AB3309

Anti-Alpha-synuclein antibody [syn204]

KO Validated
What is this?

Be the first to review this product! Submit a review

(10 Publications)

Mouse Monoclonal Alpha-synuclein antibody. Suitable for ICC and reacts with Human samples. Cited in 10 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human SNCA.

View Alternative Names

NACP, PARK1, SNCA, Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor

1 Images

Lab

Immunocytochemistry - Anti-Alpha-synuclein antibody [syn204] (AB3309)

ab3309 staining Alpha-Synuclein in wild-type Hap1 cells (top panel) and SNCA knockout Hap1 cells (bottom panel). The cells were fixed with 4% paraformaldehyde (10 min) then permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab3309 at 10μg/ml concentration and ab6046 (Rabbit polyclonal to beta Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to mouse IgG (Alexa Fluor^® 488) (ab150117) at 2 μg/ml (shown in green) and a goat secondary antibody to rabbit IgG (Alexa Fluor^® 594) (ab150080) at 2 μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI.
Image was taken with a confocal microscope (Leica-Microsystems TCS SP8).

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

syn204

Isotype

IgG2a

Light chain type

kappa

Carrier free

Reacts with

Human

Applications

ICC

applications

Immunogen

Recombinant Full Length Protein corresponding to Human SNCA.

P37840

Specificity

Due to sequence homology ab3309 might react with Beta synuclein

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICC-species-checked": "testedAndGuaranteed", "ICC-species-dilution-info": "10 µg/mL", "ICC-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein G

Storage buffer

pH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Alpha-synuclein often referred to by alternate names such as SNCA is a protein of around 14 kDa mass. It mainly expresses in the brain particularly in presynaptic nerve terminals. This protein functions mechanically by stabilizing synaptic vesicles and maintaining synaptic function. It exists both in soluble monomer forms and as aggregates in protein filaments. Antibodies like 4D6 and EP1536Y target monomer forms of protein for more detailed studies.

Biological function summary

The alpha-synuclein protein plays critical roles in neuronal activity. It contributes to neurotransmitter release regulation by acting in the formation and plasticity of the presynaptic neuronal network. Alpha-synuclein doesn't usually form parts of large protein complexes but it may associate transiently with membranes and vesicular structures. The protein's monomer form has also been observed in alpha lines and related neuronal processes operating alongside various cellular functions.

Pathways

Synaptic vesicle trafficking and dopamine neurotransmitter release are significant areas involving the alpha-synuclein protein. In these pathways alpha-synuclein interacts with other proteins like synaptophysin and protein monomer monomerizations are intrinsic to these processes. Altered function or aggregation of alpha-synuclein disrupts these pathways influencing broader neurological functions.

Alterations or accumulations of alpha-synuclein are strongly linked to Parkinson's disease and Lewy body dementia. In these conditions alpha-synuclein forms abnormal protein filaments known as Lewy bodies within neurons. These formations disrupt cellular processes and neuron health. Synucleinopathies such as these show connections with proteins like parkin and DJ-1 which also have key roles in these neurodegenerative diseases.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed : 20798282, PubMed : 26442590, PubMed : 28288128, PubMed : 30404828). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed : 28288128, PubMed : 30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed : 30404828). Also acts as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed : 20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed : 20798282). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed : 26442590).

See full target information SNCA

style

left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Cells 11: PubMed36230952

2022

ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson's Disease-like Behavior.

Applications

Unspecified application

Species

Unspecified reactive species

Fei Gao,Han Zhang,Jia Yang,Menghua Cai,Qi Yang,Huaishan Wang,Yi Xu,Hui Chen,Yu Hu,Wei He,Jianmin Zhang

Frontiers in neuroscience 14:575459 PubMed33408606

2020

Neuroprotective and Neurorestorative Effects of Extract in the MPTP/MPP-Induced Mouse and Cellular Models of Parkinson's Disease.

Applications

Unspecified application

Species

Unspecified reactive species

Kunwadee Noonong,Prasert Sobhon,Morakot Sroyraya,Kulathida Chaithirayanon

Neural regeneration research 15:361-368 PubMed31552910

2019

Ethanol extract from ameliorates dopaminergic neuronal cell death in transgenic mice expressing mutant A53T human alpha-synuclein.

Applications

Unspecified application

Species

Unspecified reactive species

Hyun Jin Park,Ting Ting Zhao,Seung Hwan Kim,Chong Kil Lee,Bang Yeon Hwang,Kyung Eun Lee,Myung Koo Lee

eLife 8: PubMed31389332

2019

An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils.

Applications

Unspecified application

Species

Unspecified reactive species

Emil Dandanell Agerschou,Patrick Flagmeier,Theodora Saridaki,Céline Galvagnion,Daniel Komnig,Laetitia Heid,Vibha Prasad,Hamed Shaykhalishahi,Dieter Willbold,Christopher M Dobson,Aaron Voigt,Bjoern Falkenburger,Wolfgang Hoyer,Alexander K Buell

Biochimica et biophysica acta. Molecular basis of 1864:3714-3725 PubMed30290273

2018

C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.

Applications

Unspecified application

Species

Unspecified reactive species

Liang Ma,Chen Yang,Xia Zhang,Yang Li,Shun Wang,Ling Zheng,Kun Huang

Neurochemistry international 120:172-181 PubMed30099122

2018

Yeast red pigment modifies cloned human α-synuclein pathogenesis in Parkinson disease models in Saccharomyces cerevisiae and Drosophila melanogaster.

Applications

Unspecified application

Species

Unspecified reactive species

O V Nevzglyadova,E V Mikhailova,A V Artemov,Y E Ozerova,P A Ivanova,I M Golomidov,O I Bolshakova,V V Zenin,E I Kostyleva,T R Soidla,S V Sarantseva

JAMA neurology 74:163-172 PubMed27918765

2016

Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.

Applications

Unspecified application

Species

Unspecified reactive species

Mohammad Shahnawaz,Takahiko Tokuda,Masaaki Waragai,Nicolas Mendez,Ryotaro Ishii,Claudia Trenkwalder,Brit Mollenhauer,Claudio Soto

Proceedings of the National Academy of Sciences of the United States of America 113:9593-8 PubMed27482103

2016

Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.

Applications

SDS-PAGE

Species

Unspecified reactive species

Fares Bassil,Pierre-Olivier Fernagut,Erwan Bezard,Alain Pruvost,Thierry Leste-Lasserre,Quyen Q Hoang,Dagmar Ringe,Gregory A Petsko,Wassilios G Meissner

Nature protocols 9:2135-46 PubMed25122523

2014

Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Applications

Unspecified application

Species

Unspecified reactive species

Laura A Volpicelli-Daley,Kelvin C Luk,Virginia M-Y Lee

Neuropathology and applied neurobiology 32:351-6 PubMed16640654

2006

Comparative study of commercially available anti-alpha-synuclein antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

E Croisier,D Elfant MRes,M Deprez,K Goldring,D T Dexter,R K B Pearce,M B Graeber,F Roncaroli

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Alpha-synuclein antibody [syn204]

Immunocytochemistry - Anti-Alpha-synuclein antibody [syn204] (AB3309)

Key facts

Host species

Clonality

Clone number

Isotype

Light chain type

Carrier free

Reacts with

Applications

Immunogen

Specificity

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (10)

Product promise